Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway.
Sign Up to like & getrecommendations! Published in 2024 at "Clinical science"
DOI: 10.1042/cs20240302
Abstract: Excessive activation of the mineralocorticoid receptor (MR) is implicated in cardiovascular and renal disease. Decreasing MR activation with MR antagonists (MRA) is effective to slow chronic kidney disease (CKD) progression and its cardiovascular comorbidities in… read more here.
Keywords: modulator balcinrenone; eplerenone; activation; mineralocorticoid receptor ... See more keywords